OncoMatch

OncoMatch/Clinical Trials/NCT06393738

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Is NCT06393738 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ARV-393 and Glofitamab for relapsed/refractory (r/r) mature b cell non hodgkin lymphoma (nhl).

Phase 1RecruitingArvinas Inc.NCT06393738Data as of May 2026

Treatment: ARV-393 · Glofitamab — This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Must have received: systemic therapy (rituximab)

relapsed/refractory NHL and 2 prior systemic therapies, (including rituximab)

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant (SCT)

Cannot have received: solid organ transplantation

Prior...solid organ transplantation

Lab requirements

Blood counts

Adequate bone marrow function

Kidney function

Adequate kidney function

Liver function

Adequate Liver Function

Cardiac function

Cardiac ejection fraction <45% excluded; no clinically relevant ECG abnormalities; no serious conduction system abnormalities; no symptomatic CHF NYHA Class III or IV

Adequate bone marrow function; Adequate kidney function; Adequate Liver Function; Standard 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results; Cardiac ejection fraction <45%.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Clinical Trial Site · New Haven, Connecticut
  • Clinical Trial Site · Detroit, Michigan
  • Clinical Trial Site · New Brunswick, New Jersey
  • Clinical Trial Site · New York, New York
  • Clinical Trial Site · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify